403 related articles for article (PubMed ID: 21076461)
21. Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype.
Xu WH; Liu ZB; Yang C; Qin W; Shao ZM
PLoS One; 2012; 7(5):e37624. PubMed ID: 22649545
[TBL] [Abstract][Full Text] [Related]
22. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression of β-catenin in invasive ductal breast carcinomas.
Abd El-Rehim D; Ali MM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):185-95. PubMed ID: 21057570
[TBL] [Abstract][Full Text] [Related]
24. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
[TBL] [Abstract][Full Text] [Related]
25. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type.
Nomura R; Saito T; Mitomi H; Hidaka Y; Lee SY; Watanabe S; Yao T
Hum Pathol; 2014 Dec; 45(12):2488-96. PubMed ID: 25288233
[TBL] [Abstract][Full Text] [Related]
26. The majority of β-catenin mutations in colorectal cancer is homozygous.
Arnold A; Tronser M; Sers C; Ahadova A; Endris V; Mamlouk S; Horst D; Möbs M; Bischoff P; Kloor M; Bläker H
BMC Cancer; 2020 Oct; 20(1):1038. PubMed ID: 33115416
[TBL] [Abstract][Full Text] [Related]
27. Altered expression and mutation of beta-catenin gene in gastric carcinomas and cell lines.
Woo DK; Kim HS; Lee HS; Kang YH; Yang HK; Kim WH
Int J Cancer; 2001 Mar; 95(2):108-13. PubMed ID: 11241321
[TBL] [Abstract][Full Text] [Related]
28. Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study.
Rakha EA; Teoh TK; Lee AH; Nolan CC; Ellis IO; Green AR
Histopathology; 2013 Apr; 62(5):695-701. PubMed ID: 23347178
[TBL] [Abstract][Full Text] [Related]
29. Distinctive Patterns of CTNNB1 (β-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Jo VY; Sholl LM; Krane JF
Am J Surg Pathol; 2016 Aug; 40(8):1143-50. PubMed ID: 27259009
[TBL] [Abstract][Full Text] [Related]
30. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
Prasad CP; Gupta SD; Rath G; Ralhan R
Oncology; 2007; 73(1-2):112-7. PubMed ID: 18337623
[TBL] [Abstract][Full Text] [Related]
31. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
Fattet S; Haberler C; Legoix P; Varlet P; Lellouch-Tubiana A; Lair S; Manie E; Raquin MA; Bours D; Carpentier S; Barillot E; Grill J; Doz F; Puget S; Janoueix-Lerosey I; Delattre O
J Pathol; 2009 May; 218(1):86-94. PubMed ID: 19197950
[TBL] [Abstract][Full Text] [Related]
32. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.
Goyal A; Martin TA; Mansel RE; Jiang WG
World J Surg Oncol; 2008 Jun; 6():56. PubMed ID: 18547424
[TBL] [Abstract][Full Text] [Related]
33. Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype.
Mahler-Araujo B; Savage K; Parry S; Reis-Filho JS
J Clin Pathol; 2008 May; 61(5):615-20. PubMed ID: 18156431
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
[TBL] [Abstract][Full Text] [Related]
35. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
[TBL] [Abstract][Full Text] [Related]
36. HGF/c-Met related activation of β-catenin in hepatoblastoma.
Purcell R; Childs M; Maibach R; Miles C; Turner C; Zimmermann A; Sullivan M
J Exp Clin Cancer Res; 2011 Oct; 30(1):96. PubMed ID: 21992464
[TBL] [Abstract][Full Text] [Related]
37. Assessment of CTNNB1 gene mutations and β-catenin immunoexpression in salivary gland pleomorphic adenomas and adenoid cystic carcinomas.
Cavalcante RB; Nonaka CFW; Santos HBP; Rabenhorst SHB; Pereira Pinto L; de Souza LB
Virchows Arch; 2018 Jun; 472(6):999-1005. PubMed ID: 29577164
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic characteristics of FBXW7-mutated colorectal adenocarcinoma and association with aberrant beta-catenin localization.
Escobar D; Bushara O; Sun L; Liao J; Yang GY
Hum Pathol; 2022 Jan; 119():51-58. PubMed ID: 34717891
[TBL] [Abstract][Full Text] [Related]
39. Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast.
Prasad CP; Rath G; Mathur S; Bhatnagar D; Parshad R; Ralhan R
BMC Cancer; 2009 Sep; 9():325. PubMed ID: 19751508
[TBL] [Abstract][Full Text] [Related]
40. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
